A randomised, double-blind, placebo- and active-comparator controlled, 4-arm, parallel-group, 26 week multicentre study with a 26 week extension, to evaluate the efficacy, safety, and tolerability of JNJ-28431754 (Canagliflozin) versus placebo and sitagliptin in the treatment of subjects with type 2 diabetes mellitus with inadequate glycaemic control on metformin and sulphonylurea therapy

Trial Profile

A randomised, double-blind, placebo- and active-comparator controlled, 4-arm, parallel-group, 26 week multicentre study with a 26 week extension, to evaluate the efficacy, safety, and tolerability of JNJ-28431754 (Canagliflozin) versus placebo and sitagliptin in the treatment of subjects with type 2 diabetes mellitus with inadequate glycaemic control on metformin and sulphonylurea therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Canagliflozin (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 22 Nov 2010 Status changed from not yet recruiting to recruiting.
    • 08 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top